Bio Green Med Solution, Inc 8-K, filed Aug 26, 2020
Bio Green Med Solution, Inc. (BGMS)
About this 8-K
Bio Green Med Solution, Inc filed this 8-K on August 26, 2020.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest eventreported): August 26, 2020
CYCLACEL PHARMACEUTICALS, INC.
(Exact name of registrant as specifiedin its charter)
| Delaware | 0-50626 | 91-1707622 |
|---|---|---|
| (State or other jurisdiction<br><br> <br>of incorporation) | (Commission File Number) | (IRS Employer<br><br> <br>Identification No.) |
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
(Address of principal executive officesand zip code)
Registrant’s telephone number,including area code: (908) 517-7330
(Former Name or Former Address, if ChangedSince Last Report)
Check the appropriatebox below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of thefollowing provisions (seeGeneral Instruction A.2. below):
| ¨ | Written communicationspursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting materialpursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communicationspursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement communicationspursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | CYCC | The Nasdaq Stock Market LLC |
| Preferred Stock, $0.001 par value | CYCCP | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
|---|
Dr. David U’Prichard, Chairman of the Board of Directors (the “Board”) of Cyclacel Pharmaceuticals, Inc. (the “Company”), has informed the Board of his intent to take a medical leave of absence from his service on the Board and from all committees thereof. Effective August 26, 2020, Dr. Christopher Henney, Vice Chairman of the Board, will serve as Chairman of the Board during Dr. U’Prichard’s absence.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CYCLACEL PHARMACEUTICALS, INC. | |
|---|---|
| By: | /s/ Paul McBarron |
| Name: | Paul McBarron |
| Title: | Executive Vice President—Finance, |
| Chief Financial Officer and Chief Operating Officer |
Date: August 26, 2020